Validating the 2022 <scp>WHO</scp> classification in thyroid carcinomas: Prospective evidence for predicting iodine resistance
The 2022 WHO classification improves RAIR disease prediction, notably by recognizing high-grade carcinomas as a distinct entity. High-grade factors, especially tumour necrosis, which emerges as a key predictive factor, should be systematically reported in thyroid carcinoma pathology reports to enhance patient management and follow-up.
Authors
- Mirela Diana Ilie (ORCID: https://orcid.org/0000-0001-7248-7258)
- Myriam Decaussin‐Petrucci (ORCID: https://orcid.org/0000-0002-6065-0756)
- C. Bournaud
- L. Mebarki
- Françoise Descôtes
- Mireille Bertholon‐Grégoire
- Hélène Lasolle
- Fabien Subtil
- Elise André
- Jean‐Christophe Lifante
- Françoise Borson‐Chazot
Institutions
- Université Claude Bernard Lyon 1 (FR)
- Centre National de la Recherche Scientifique (FR)
- Inserm (FR)
- Communauté urbaine de Lyon (FR)
- Hospices Civils de Lyon (FR)
- Hôpital Jeanne de Flandre (FR)
- Hôpital Lyon Sud (FR)
- Centre de Recherche en Cancérologie de Lyon (FR)
- Laboratoire de Biométrie et Biologie Evolutive (FR)
Publication Details
- Journal
- Histopathology
- Published
- 2026-03-28
- DOI
- https://doi.org/10.1111/his.70148
- Primary Topic
- Thyroid Cancer Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00